These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11314752)

  • 1. Clinical application of 5alpha-reductase inhibitors.
    Cilotti A; Danza G; Serio M
    J Endocrinol Invest; 2001 Mar; 24(3):199-203. PubMed ID: 11314752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study.
    Vaarala MH; Lukkarinen O; Marttila T; Kyllönen AP; Porvari KS; Vihko PT
    World J Urol; 2000 Dec; 18(6):406-10. PubMed ID: 11204259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
    Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
    Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finasteride: a clinical review.
    Gormley GJ
    Biomed Pharmacother; 1995; 49(7-8):319-24. PubMed ID: 8562856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.
    Chen W; Zouboulis CC; Orfanos CE
    Dermatology; 1996; 193(3):177-84. PubMed ID: 8944337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms].
    Wirth MP; Helke C; Froschermaier SE
    Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?].
    Spinucci G; Pasquali R
    Clin Ter; 1996 Jun; 147(6):305-15. PubMed ID: 8925640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical applications of five-alpha reductase inhibitors.
    Loughlin KR
    Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
    Azzouni F; Zeitouni N; Mohler J
    J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
    Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
    Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview on 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
    Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.